Combined liver-kidney transplants: Allosensitization and recipient outcomes

Transplantation

Volumn 91, Issue 11, 2011, Pages 1286-1292

  Askar, Medhat ^a,c   Schold, Jesse D ^a   Eghtesad, Bijan ^a   Flechner, Stuart M ^a   Kaplan, Bruce ^b   Klingman, Lynne ^a   Zein, Nizar N ^a   Fung, John ^a   Srinivas, Titte R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Allograft survival; Allosensitization; Combined transplants; Kidney transplantation; Liver transplantation; Patient survival

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ALLOSENSITIZATION; ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HALF LIFE TIME; HUMAN; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SENSITIZATION; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSION; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79958290840     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182184181     Document Type: Article

References (34)

1. Margreiter R, Kramar R, Huber C, et al. Combined liver and kidney transplantation. Lancet 1984; 1: 1077.
2. Fung J, Makowka L, Tzakis A, et al. Combined liver-kidney transplantation: Analysis of patients with preformed lymphocytotoxic antibodies. Transplant Proc 1988; 20: 88.
3. Kissmeyer-Nielsen F, Olsen S, Petersen VP, et al. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966; 2: 662.
4. Kamada N, Davies HS, Roser B. Reversal of transplantation immunity by liver grafting. Nature 1981; 292: 840.
5. Starzl TE, Demetris AJ, Todo S, et al. Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clinical Transplantation 1989; 3: 37.
6. Eid A, Moore SB, Wiesner RH, et al. Evidence that the liver does not always protect the kidney from hyperacute rejection in combined liverkidney transplantation across a positive lymphocyte crossmatch. Transplantation 1990; 50: 331.
7. Hadaya K, Ferrari-Lacraz S, Giostra E, et al. Humoral and cellular rejection after combined liver-kidney transplantation in low immunologic risk recipients. Transpl Int 2009; 22: 242.
8. Reichman TW, Marino SR, Milner J, et al. Acute humoral rejection in an ABO compatible combined liver-kidney transplant-the kidney is not always protected. Am J Transplant 2009; 9: 1957.
9. Saidman SL, Duquesnoy RJ, Demetris AJ, et al. Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol 1994; 2: 61.
10. Freeman RB Jr, Wiesner RH, Harper A, et al. The new liver allocation system: Moving toward evidence-based transplantation policy. Liver Transpl 2002; 8: 851.
11. Dube GK, Cohen DJ. Simultaneous liver and kidney transplantation. Curr Opin Nephrol Hypertens 2007; 16: 547.
12. Katznelson S, Cecka JM. The liver neither protects the kidney from rejection nor improves kidney graft survival after combined liver and kidney transplantation from the same donor. Transplantation 1996; 61: 1403.
13. Fong TL, Bunnapradist S, Jordan SC, et al. Analysis of the United Network for Organ Sharing database comparing renal allografts and patient survival in combined liver-kidney transplantation with the contralateral allografts in kidney alone or kidney-pancreas transplantation. Transplantation 2003; 76: 348.
14. Bryan CF, Aeder MI, Helling TS, et al. Clinical relevance of a positive B-cell crossmatch on renal transplantation: A multi-transplant center evaluation. Transplant Proc 1993; 25: 247.
15. Mahoney RJ, Taranto S, Edwards E. B-cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients. Hum Immunol 2002; 63: 324.
16. Eng HS, Bennett G, Tsiopelas E, et al. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 2008; 8: 2335.
17. Rosenberg JC, Beyersdorf TM, Derbyshire N, et al. Retrieval and allocation of organs for transplantation: The Michigan experience. Clin Transpl 1993: 335.
18. Katznelson S, Bhaduri S, Cecka JM. Clinical aspects of sensitization. Clin Transpl 1997: 285.
19. Pour-Reza-Gholi F, Daneshvar S, Nafar M, et al. Potential risk factors for hypersensitization reflected by panel-reactive antibodies in dialysis patients. Transplant Proc 2005; 37: 2936.
20. Ishida H, Tanabe K, Furusawa M, et al. Evaluation of flow cytometric panel reactive antibody in renal transplant recipients-Examination of 238 cases of renal transplantation. Transpl Int 2005; 18: 163.
21. Miura M, Kubota KC, Itoh T, et al. Positive pre-transplant flow-panel reactive antibody detected after accelerated acute rejection with negative pre-transplant flow crossmatch. Clin Transplant 2006; 20(suppl 15): 33.
22. Bielmann D, Honger G, Lutz D, et al. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 2007; 7: 626.
23. Dunn TB, Ozturk OG, Noreen H, et al. Impact of flow XM results on kidney transplant outcomes for recipients with donor specific antibody (DSA) [abstract]. Am J Transplant 2010; 10 (suppl 4): 236.
24. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
25. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520.
26. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibodymediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68.
27. Cai J, Terasaki PI, Anderson N, et al. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. Transplantation 2009; 88: 226.
28. Kaplan B, Meier-Kriesche HU. Death after graft loss: An important late study endpoint in kidney transplantation.AmJ Transplant 2002; 2: 970.
29. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
30. Askar M, Smith G, Klingman L, et al. Liver transplantation significantly decreases donor HLA specific antibodies in some but not all sensitized recipients of combined liver/kidney transplants [abstract]. Int J Immunogenet 2010; 37: 417.
31. Manez R, Kelly RH, Kobayashi M, et al. Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: Studies toward further defining their significance. Hepatology 1995; 21: 1345.
32. Olausson M, Mjornstedt L, Norden G, et al. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized crossmatch positive recipients. Am J Transplant 2007; 7: 130.
33. Flechner SM, Fatica R, Askar M, et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010; 90: 1486.
34. DickinsonDM,Arrington CJ, Fant G, et al.SRTRprogram-specific reports on outcomes: A guide for the new reader. Am J Transplant 2008; 8: 1012.